We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03330197
Recruitment Status : Terminated (Sponsor decision due to slow accrual)
First Posted : November 6, 2017
Last Update Posted : November 11, 2021
Information provided by (Responsible Party):
Alaunos Therapeutics

Brief Summary:

This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.

The main purpose of this study is to evaluate the safety and tolerability of a single tumor injection of Ad-RTS-hIL-12 given with oral veledimex in the pediatric population.

Condition or disease Intervention/treatment Phase
Pediatric Brain Tumor Diffuse Intrinsic Pontine Glioma Biological: Ad-RTS-hIL-12 Drug: Oral Veledimex - Arm 1 (Pediatric Brain Tumor) Drug: Oral Veledimex - Arm 2 (DIPG) Phase 1 Phase 2

Detailed Description:

Eligible patients will be stratified to one of two arms, according to clinical indication for tumor resection. Pediatric patients who are scheduled for craniotomy and tumor resection will receive one dose of veledimex before the resection procedure. Ad-RTS-hIL-12 will be administered by free-hand injection. Patients will continue on oral veledimex for 14 days. This arm has been completed and is currently closed to enrollment.

Pediatric patients with diffuse intrinsic pontine glioma (DIPG) will receive Ad-RTS-hIL-12 by stereotactic injection and then will continue on oral veledimex for 14 days.

The study is divided into three periods: the screening period, the treatment period and the follow-up period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects
Actual Study Start Date : September 26, 2017
Actual Primary Completion Date : September 10, 2021
Actual Study Completion Date : September 10, 2021

Arm Intervention/treatment
Experimental: Arm 1 - Closed
Intratumoral Ad-RTS-hIL-12 freehand injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors.
Biological: Ad-RTS-hIL-12
2.0 x 10^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12

Drug: Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
1 dose level (10mg/day) 15 oral daily doses of veledimex

Experimental: Arm 2 - Open
Intratumoral Ad-RTS-hIL-12 stereotactic injection and oral veledimex (activator ligand) in pediatric patients with DIPG.
Biological: Ad-RTS-hIL-12
2.0 x 10^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12

Drug: Oral Veledimex - Arm 2 (DIPG)
2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex

Primary Outcome Measures :
  1. The safety and tolerability of intratumoral Ad-RTS-hIL-12 and veledimex as measured by dose limiting toxicities and compliance. [ Time Frame: From Day 0 through Day 56 ]

Secondary Outcome Measures :
  1. To measure the veledimex in blood and brain tumor by using the LC-MS method [ Time Frame: From Day 0 through 30 days after the last dose of veledimex ]
  2. Evaluate preliminary efficacy of Ad-RTS-hIL-12 and veledimex by assessing survival and tumor response rates [ Time Frame: 2 Years ]
  3. Measure immune response of Ad-RTS-hIL-12 and veledimex by a quantitative multiplex immunoassay for determination of IL-12 and IFNg levels [ Time Frame: 28 Days ]
  4. Subjects with Ad-RTS-hIL-12 and veledimex related adverse events will be assessed for safety by CTCAE v5.0 [ Time Frame: 2 Years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   0 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects ≤ 21 years-of-age with the demonstrated ability to swallow capsules whole and who are willing to provide access to previously obtained biopsy results
  2. Provision of written informed consent and assent, when applicable, for tumor resection, stereotactic surgery, tumor biopsy, sample collection, and/or treatment with study drug prior to undergoing any study-specific procedures
  3. Arm 1: Evidence of recurrent or progressive supratentorial tumor, which has shown a > 25% increase in bi dimensional measurements by MRI or is refractory with significant neuro deterioration that is not otherwise explained with no known curative therapy, not in direct continuity with the ventricular system (e.g., there is physical separation between the tumor and ventricle, the tumor does not open directly into the ventricular system).

    Arm 2: Clinical presentation of DIPG and compatible MRI with approximately 2/3 of the pons included and without evidence of dissemination. Subjects should be ≥ 2 weeks and ≤ 10 weeks post standard focal radiotherapy (ie, dose of 5400 to 5960 cGy and maximum dexamethasone of 1 mg/m2/day)

  4. At the time of registration, subjects must have recovered from the toxic effects of previous treatments, as determined by the treating physician.

    1. Targeted agents, including small-molecular tyrosine kinase inhibitors: 2 weeks
    2. Other cytotoxic agents: 3 weeks
    3. Nitrosoureas: 6 weeks
    4. Monoclonal antibody immunotherapies (eg, PD-1, CTLA-4): 6 weeks
    5. Vaccine-based and/or viral therapy: 3 months
  5. On a stable or decreasing dose of dexamethasone for the previous 7 days
  6. Able to undergo standard MRI scans with contrast agent before enrollment and after treatment
  7. Have age-appropriate functional performance:

    1. Lansky score ≥ 40 or
    2. Karnofsky score > 50 or
    3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2
  8. Have adequate bone marrow reserves and liver and kidney function, as assessed by the following laboratory requirements:

    1. Hemoglobin ≥ 8 g/L
    2. Absolute lymphocyte count ≥ 500/mm3
    3. Absolute neutrophil count ≥ 1000/mm3
    4. Platelets ≥ 100,000/mm3 (untransfused [> 5 days] without growth factors)
    5. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) for age
    6. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN for age
    7. Total bilirubin < 1.5 x ULN for age
    8. International normalized ratio (INR) and activated thromboplastin time within normal institutional limits
  9. Male and female subjects of childbearing potential must agree to use a highly reliable method of birth control (expected failure rate < 1% per year) from the Screening visit through 28 days after the last dose of study drug. Women of childbearing potential must have a negative pregnancy test at screening.

Exclusion Criteria:

  1. Radiotherapy treatment prior to the first veledimex dose:

    1. Focal radiation ≤ 4 weeks
    2. Whole-brain radiation ≤ 6 weeks
    3. Cranio-spinal radiation ≤ 12 weeks NOTE: Subjects in Arm 2 (ie, with DIPG) must be ≥ 2 weeks and ≤ 10 weeks after standard focal radiotherapy (dose of 5400 to 5960 cGy and maximum dexamethasone of 1 mg/m2/day)
  2. Subjects with clinically significant increased intracranial pressure (eg, impending herniation or requirement for immediate palliative treatment) or uncontrolled seizures
  3. Subjects whose body surface area (BSA) would expose them to < 75% or > 125% of the target dose
  4. Known immunosuppressive disease, autoimmune condition, and/or chronic viral infection (eg, human immunodeficiency virus [HIV], hepatitis)
  5. Use of systemic antibacterial, antifungal, or antiviral medications for the treatment of acute clinically significant infection within 2 weeks of first veledimex dose. Concomitant therapy for chronic infections is not allowed. Subjects must be afebrile prior to Ad-RTS-hIL-12 injection; only prophylactic antibiotic use is allowed perioperatively
  6. Use of enzyme-inducing antiepileptic drugs (EIAEDs) within 7 days prior to the first dose of study drug
  7. Other concurrent clinically active malignant disease, requiring treatment
  8. Nursing or pregnant females
  9. Prior exposure to veledimex
  10. Use of medications that induce, inhibit, or are substrates of cytochrome p450 (CYP450) 3A4 within 7 days prior to veledimex
  11. Use of heparin or acetylsalicylic acid (ASA). The use of systemic heparinization, or any ASA containing medications, is prohibited during active dosing with veledimex. Prophylactic heparin SC, per institutional protocol, or heparin when used for maintaining patency of an access port of a PICC line is permitted.
  12. Presence of any contraindication for a neurosurgical procedure
  13. Unstable or clinically significant concurrent medical condition that would jeopardize the safety of a subject and/or their compliance with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03330197

Layout table for location information
United States, California
University of California San Francisco, Benioff Children's Hospital
San Francisco, California, United States, 94158
United States, Illinois
Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, Massachusetts
Dana- Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Alaunos Therapeutics
Layout table for investigator information
Study Director: Jill Buck ZIOPHARM Oncology, Inc.
Layout table for additonal information
Responsible Party: Alaunos Therapeutics
ClinicalTrials.gov Identifier: NCT03330197    
Other Study ID Numbers: ATI001-103
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: November 11, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alaunos Therapeutics:
Anaplastic Astrocytoma
High Grade Glioma (HGG) Not Otherwise Specified (NOS)
Supratentorial Tumor NOS
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Neoplasms
Diffuse Intrinsic Pontine Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Brain Stem Neoplasms
Infratentorial Neoplasms